UBE2M and cancer: Notably, MLN4924 [90–95], which is also known as pevonedistat, is a first-in-class inhibitor of the NAE used in cancer treatment and regulates UBE2M and UBE2F in different ways; MLN4924 causes a dose- and time-dependent increase in UBE2M levels but a decrease in UBE2F levels [89].